Elizabeth Brandt, MD
Nephrology · Lebanon, NHNPI 1275700049
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,750 of the $40,847 with a category attached, or 60.6%. Every reported general payment came from a single manufacturer, Amgen. Among nephrology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $949.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$41K
Across 1 payment — averaging $72,352 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$72K
What the payments were for
- Consulting fees$11,97929%
- Speaking & faculty fees$24,75061%
- Travel & lodging$3,5319%
- Food & beverage$5881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 43 | $40,847 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$32,609
How this compares
$40,847 in reported general payments places this provider in the 95th percentile of 33 nephrology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 22 | $2,701 |
| Ezetimibe | 40 | $1,030 |
| Cinacalcet Hcl | 25 | $1,000 |
| Calcitriol | 53 | $895 |
| Allopurinol | 49 | $880 |
| Furosemide | 55 | $777 |
| Terazosin Hcl | 16 | $744 |
| Losartan Potassium | 34 | $421 |
| Metoprolol Succinate | 14 | $291 |
| Lisinopril | 39 | $282 |
| Atorvastatin Calcium | 16 | $276 |
| Amlodipine Besylate | 38 | $258 |
| Spironolactone | 11 | $124 |
| Rosuvastatin Calcium | 12 | $100 |
| Hydrochlorothiazide | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Lebanon
- Sudip GhimireLebanon$303
- Marios PrikisLebanon$245
- Clay BlockLebanon$20
- Martha GraberLebanon$16
- Michael ChobanianLebanon$0
- Charles HopleyLebanon$0
- Kanza HaqLebanon$0
- Brian RemillardLebanon$0
- Thomas KanekoLebanon$0
- Ana StankovicSalem$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.